Conference Correspondent

Conference Correspondent

A quantitative analysis revealed substantially different activity profiles for ibrutinib and chlorambucil in the circulating cells during the first year of treatment in patients with chronic lymphocytic leukemia (CLL).
This 2-cohort, phase 2 study will investigate a CD19 antibody, MOR208, combined with idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were previously treated with a Bruton’s tyrosine kinase inhibitor.
This phase 1 trial evaluates the safety and efficacy of the triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with B-cell malignancies.
Researchers are evaluating ibrutinib with prednisone as a potential treatment option for patients with newly diagnosed moderate or severe chronic graft-versus-host disease (cGVHD).
This 4-year follow-up of the phase 3 RESONATE study provides updated data on the efficacy and safety of ibrutinib, comparing the long-term efficacy and safety of ibrutinib versus ofatumumab in patients with chronic lymphocytic leukemia (CLL).
GENUINE, the first randomized phase 3 trial conducted to assess the addition of a novel agent, ublituximab, to ibrutinib in high-risk, relapsed/refractory chronic lymphocytic leukemia (CLL), evaluates ibrutinib monotherapy versus ublituximab and ibrutinib.
CALGB 10404, a randomized phase 2 study, compares different fludarabine chemoimmunotherapy regimens in patients with non-del(11q) chronic lymphocytic leukemia (CLL).
This retrospective cohort study examines the use and efficacy of ibrutinib in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter transformation.

Although two-thirds of patients with newly diagnosed acute myeloid leukemia (AML) are tested for recurrent mutations, most do not receive the complete panel of guideline-recommended tests.

The majority of newly diagnosed patients with acute myeloid leukemia (AML) were found to be minimal residual disease (MRD)-negative after induction with a crenolanib-containing regimen.

Page 10 of 16
Results 91 - 100 of 153
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME